INTRODUCTION
Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm and
represents less than 1% of all primary breast tumors1. Its incidence is approximately 2.1 per million
population and occurs mostly in women aged 45-49 years2,3. PT
generally has a rapid growth rate and measures between 4 to 7 cm, but when it
reaches a size greater than 10 cm it is considered giant2.
According to the World Health Organization (WHO), PTs are histopathological
classified as benign, malignant, and borderline3. Borderline PT has a frequency of 12% to
26%1,3, a recurrence rate of 15% to 25%, and a low
potential for metastasis4.
Histopathologic features include a circumscribed or focally invasive borderline,
frequent mitoses, and moderate and/or atypical stromal cellularity1.
The recommended treatment for all types of PT is surgical excision5. To avoid local recurrence, it
is recommended to achieve a free margin of at least 1 cm. In general, tumors
larger than 5 cm are treated by mastectomy5,6. However, the
final treatment will depend on the histopathologic classification of the tumor,
size, extent, and location. When deciding to perform a wide surgical resection
of a Giant Borderline PT, it is necessary to consider different reconstructive
techniques, either implant-based reconstruction (IBR) or autologous
reconstruction (AR) based on flaps7. Quality of life, self-esteem and psychosocial wellbeing
tend to improve in women who have undergone reconstructive surgery after
mastectomy8.
We present the case of a 46-year-old woman with a Recurrent Giant Borderline PT
in the left breast of approximately 40 cm in diameter, who underwent a wide
resection with mastectomy and immediate breast reconstruction employing a
latissimus dorsi flap (LDF) plus fat grafting injection and who had a favorable
evolution after surgery without complications or recurrences.
CASE REPORT
A 46-year-old female patient, without comorbidities, with a history of lumpectomy
for a PT in the left breast 4 years ago. Previously, she went to the
consultation referring to a reappearance of the tumor in the left breast. On
physical examination, a peri-areolar surgical scar was observed in the left
breast in the upper outer quadrant and a hard, slightly mobile tumor
approximately 8 cm in diameter was palpated. A biopsy was performed, which
revealed recurrent PT. Due to the restrictions imposed by the COVID-19 pandemic
in Peru, contact with the patient was lost and the correct follow-up was not
carried out.
Nine months later, the patient came to the emergency room due to an increase in
the size of the tumor and the presence of intense pain in the left breast. On
physical examination, the left breast revealed pain on palpation, a slightly
mobile tumor of approximately 40 cm in diameter, and erythema with collateral
venous circulation (Figure 1).
Figure 1 - Giant PT of the left breast (arrow) that occupies the entire left
breast volume and respects the mammary sulcus. There is evidence (*)
of abundant collateral circulation, extensive erythema and diffuse
circular areas of violaceous coloration.
Figure 1 - Giant PT of the left breast (arrow) that occupies the entire left
breast volume and respects the mammary sulcus. There is evidence (*)
of abundant collateral circulation, extensive erythema and diffuse
circular areas of violaceous coloration.
The findings found in the ultrasound study were compatible with the BIRADS2
category, describing a vascularized, predominantly solid tumor with welldefined
margins and cystic foci of approximately 15 cm. There was no evidence of distant
metastases on magnetic resonance imaging (MRI) and computed tomography (CT).
The
initial histopathological results of the biopsy concluded the presence of
fibroepithelial neoplasia with mild atypia, corresponding to a Borderline
PT.
Because of the findings, it was decided to perform a left total mastectomy plus
immediate breast reconstruction. The left total mastectomy was performed by the
Gynecologic Oncology Service. Initially, a low axillary dissection and a Steward
incision were performed, then an upper flap was formed with the inferior
clavicular border as limit, and an inferior flap with the sub mammary sulcus,
the anterior border of the latissimus dorsi and the sternal border as limits.
Subsequently, the tumor tissue of the left breast was excised, dissecting down
to the aponeurosis of the pectoralis major (Figure 2).
Figure 2 - A: Mastectomy specimen in which the tumor is
included. B: Left mastectomy with radical resection of
the PT, showing (*) aponeurosis of the pectoralis major.
Figure 2 - A: Mastectomy specimen in which the tumor is
included. B: Left mastectomy with radical resection of
the PT, showing (*) aponeurosis of the pectoralis major.
Lymphadenopathies of approximately 2 cm were found in axillary group I and the
corresponding excision was performed. The histopathological characteristics of
the postoperative specimen were consistent with a Borderline PT. Stromal
overgrowth, moderate atypia, cambium layer, permeative borders, and mitotic
count of 5/10 per 10 fields were evident. The surgical edges were larger than
1
mm concerning the tumor. The surrounding skin, nipple, and free terminal ducts
had no signs of malignancy. Group I lymph nodes had no signs of malignancy.
Breast reconstruction was performed by the Plastic Surgery Department. A pedicled
myocutaneous flap of the latissimus dorsi plus fat graft was performed. To
obtain the myocutaneous flap, an anterior skin incision was made up to the
latissimus dorsi muscle. Subsequently, the latissimus dorsi muscle was separated
from the serratus anterior and external oblique muscles, and an inferior
approach was made up to the iliac crest insertions and finished with a posterior
incision up to the thoracolumbar fascia over the latissimus dorsi muscle. The
flap was raised from the distal to the proximal position to locate the
latissimus dorsi pedicle (thoracodorsal artery) (Figure 3A). Subcutaneous tunneling and mobilization of the flap to
the recipient site in the left hemithorax was performed. Both the donor and
recipient areas were closed in planes (Figure 3B).
Figure 3 - A: Obtaining the myocutaneous flap, the (*) pedicled
latissimus dorsi flap is appreciated. B: Immediate
postoperative results.
Figure 3 - A: Obtaining the myocutaneous flap, the (*) pedicled
latissimus dorsi flap is appreciated. B: Immediate
postoperative results.
Hemovac drainage was placed at the end of the procedure to recover breast volume
a fat graft was placed. A tumescent solution was infiltrated in the abdomen and
a liposuction was performed, obtaining 300 cc of fat graft that was placed
intramuscularly in the mobilized LDF and the mammary region. Finally, clean
gauze and non-compressive elastic bandages were applied.
One week after surgery, the evolution of the flap was favorable with no areas of
distress or local or systemic complications. The drains progressively decreased
to less than 30 c.c.s of serohematic content and were removed. Hospital
discharge was decided and weekly outpatient controls were indicated for one
month. At one year, a CT scan was performed, which showed no signs of disease
extension. Our patient is currently under close follow-up showing a favorable
evolution with no local recurrence or distant metastasis (Figure 4).
Figure 4 - Patient comes for consultation after 18 days of surgery, showing
an adequate evolution. A: Anteriorly. B:
Laterally. C: Posterior oblique.
Figure 4 - Patient comes for consultation after 18 days of surgery, showing
an adequate evolution. A: Anteriorly. B:
Laterally. C: Posterior oblique.
DISCUSSION
Early diagnosis and staging of PT are important for timely treatment2. PT is rapidly growing and delay
in treatment can increase morbidity and mortality3. Due to social trust restrictions due to the
COVID-19 pandemic and the shift of exclusive care for COVID-19 patients to
higher-resolving hospitals, patient followup and contact was lost, leading to
tumor overgrowth.
The mainstay of PT treatment is surgical excision5,9. When
performing surgical excision, in addition to considering certain factors such
as
size, tumor extension, palpable lymph nodes, and free margins, it is necessary
to consider aesthetics for subsequent reconstruction of the affected breast.
Breast reconstruction is classified according to the type of procedure as IBR
or
AR7. Although the use
of IBR is much more frequent, it was found that AR was associated with a better
degree of satisfaction and sexual well-being compared to IBR, and it was also
found that IBR has a higher risk of long-term reconstructive failure7. Therefore, in conjunction with
the patient, we decided to perform RA instead of IBR.
In general, the RA depends on the anatomic region from which the flap originates.
Among the most frequently used are the deep inferior epigastric artery
perforator flap (DIEP), LDF, or transverse rectus abdominis myocutaneous
(TRAM)7. The LDF
provides a large amount of flexible soft tissue, anatomically the latissimus
dorsi muscle is among the largest and strongest in the body, ischemic
complications of the flap are rare due to the vascular supply provided by the
thoracodorsal artery, the posterior perforator intercostal arteries, and the
lumbar artery10.
The choice of the area to be used is determined by the patient’s body
constitution, previous surgeries, and associated comorbidities. The use of the
LDF is preferred in patients who are not candidates for the use of TRAM, due
to
previous abdominoplasty, previous TRAM, or insufficient abdominal skin and
fat10. In our case,
due to the patient’s abdominal fat and build, it was decided to use the LDF.
Concomitant to AR, fat grafting can also be performed in the area11. Among the benefits found with
the use of fat grafting are: volume augmentation with more natural results and
a
higher degree of satisfaction without the need to use prosthetic
devices11,12. In the context of autologous
reconstruction, fat graft placement can be performed late or immediately after
the transposition of the pedicled flap. Previously, a good volume gain was found
in the area after immediate fat graft injection during the reconstructive
procedure11. In our
case, it was decided to perform a fat graft injection after mobilization of the
LDF.
At present, few studies have reported reconstruction of Giant Borderline PT using
AR and fat grafting. Wang et al.13 reported total mastectomy and resection of a 30 cm diameter
Borderline PT, however, they did not report breast reconstruction. Liu et
al.14 and Zhao et
al.15 reported the
possible association between hypoglycemia and Giant Borderline PT, in both cases
radical mastectomies were performed, however, they also did not report any
breast reconstruction. Tsuruta et al.16 reported the use of a DIEP flap for breast
reconstruction after total mastectomy for Giant PT, however, they did not report
the use of fat grafting.
Adjuvant therapy such as chemotherapy and radiotherapy has not been shown to
decrease recurrence in PT9. The
local recurrence rate is 10.9%, 14.4%, and 29.6% in benign, borderline, and
malignant tumors respectively9.
Therefore, it is reasonable to monitor for at least 3 years, especially in
patients with PT with positive margins, by physical examination, ultrasound,
or
mammography17. In our
patient, monthly controls were performed in the outpatient clinic, and at one
year a control with CT was performed. There was no evidence of new masses or
tumors in the operated area and an adequate clinical evolution was observed.
CONCLUSION
In conclusion, Recurrent Giant Borderline PT is a rare pathology. Due to the
restrictions imposed by the COVID-19 pandemic, follow-up was lost, and timely
treatment was not performed. Surgical management of these tumors is a challenge
and treatment should be multidisciplinary. Breast reconstruction utilizing an
LDF plus fat graft seems to be an attractive option to obtain positive aesthetic
results.
ETHICS DECLARATIONS
Ethical approval: All procedures performed followed the ethical
standards of Ethical Principles for Medical Research Involving Human Subjects,
contained in the Declaration of Helsinki. In the present study, written informed
consent was obtained from the patient. Patient consent: The patient
provided written informed consent for the publication and the use of her
images.
REFERENCES
1. Zhang Y, Kleer CG. Phyllodes Tumor of the Breast: Histopathologic
Features, Differential Diagnosis, and Molecular/Genetic Updates. Arch Pathol
Lab
Med. 2016;140(7):665-71.
2. Liang MI, Ramaswamy B, Patterson CC, McKelvey MT, Gordillo G, Nuovo
GJ, et al.
3. Giant breast tumors: Surgical management of phyllodes tumors,
potential for reconstructive surgery and a review of literature. World J Surg
Oncol. 2008;6(1):117.
4. World Health Organization; International Agency for Research on
Cancer; Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, eds. WHO
classification of tumours of the breast. 4th ed. Lyon: International
Agency for Research on Cancer; 2012.
5. Peneş NO, Pop AL, Borş RG, Varlas VN. Large borderline phyllodes
breast tumor related to histopathology, diagnosis, and treatment management -
case report. Rom J Morphol Embryol. 2021;62(1):283-8.
6. Krings G, Bean GR, Chen YY. Fibroepithelial lesions; The WHO
spectrum. Semin Diagn Pathol. 2017;34(5):438-52.
7. Simpson A, Li P, Dietz J. Diagnosis and management of phyllodes
tumors of the breast. Ann Breast Surg. 2021;5:8-8.
8. Saldanha IJ, Cao W, Broyles JM, Adam GP, Bhuma MR, Mehta S, et al.
Breast Reconstruction After Mastectomy: A Systematic Review and Meta-Analysis
[Internet]. Rockville: Agency for Healthcare Research and Quality; 2021.
Available from: https://effectivehealthcare.ahrq.gov/products/breast-reconstructionmastectomy/research
9. Howard-McNatt MM. Patients opting for breast reconstruction
following mastectomy: an analysis of uptake rates and benefit. Breast Cancer
(Dove Med Press). 2013;5:9-15.
10. Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al.
Phyllodes tumours of the breast: a consensus review. Histopathology.
2016;68(1):5-21.
11. Sood R, Easow JM, Konopka G, Panthaki ZJ. Latissimus Dorsi Flap in
Breast Reconstruction: Recent Innovations in the Workhorse Flap. Cancer Control.
2018;25(1):1073274817744638.
12. Turner A, Abu-Ghname A, Davis MJ, Winocour SJ, Hanson SE, Chu CK.
Fat Grafting in Breast Reconstruction. Semin Plast Surg.
2020;34(1):17-23.
13. di Summa PG, Osinga R, Sapino G, Glen K, Higgins G, Tay S, et al.
Fat grafting versus implant-based treatment of breast asymmetry, a single
surgeon experience over 13 years: a paradigm shift? Gland Surg.
2021;10(6):1920-30.
14. Wang Q, Zheng K, Zhang L, Tan M, Li H, Zhang H, et al. The treatment
process of an extremely rare giant borderline phyllodes tumor of breast: case
report and literature review. Transl Cancer Res.
2021;10(4):1921-9.
15. Liu Y, Zhang M, Yang X, Zhang M, Fan Z, Li Y, et al. Severe
Hypoglycemia Caused by a Giant Borderline Phyllodes Tumor of the Breast: A Case
Report and Literature Review. Front Endocrinol (Lausanne).
2022;13:871998.
16. Zhao J, Gao M, Ren Y, Cao S, Wang H, Ge R. A Giant Borderline
Phyllodes Tumor of Breast With Skin Ulceration Leading to Non- Insular
Tumorigenic Hypoglycemia: A Case Report and Literature Review. Front Endocrinol
(Lausanne). 2021;12:651568.
17. Tsuruta Y, Karakawa R, Majima K, Yamamoto S, Shibata T, Yoshimatsu
H, et al. The Reconstruction after a Giant Phyllodes Tumor Resection Using a
DIEP Flap. Plast Reconstr Surg Glob Open. 2020;8(4):e2760.
18. National Comprehensive Cancer Network (NCCN). NCCN Guidelines
Special consideration: Phyllodes Tumor [Internet]. NCCN; 2022. Available from:
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
1. Universidad Nacional de San Agustín de
Arequipa, Arequipa, Peru
Corresponding author: Elizbet Susan
Montes-Madariaga Urb. José Luis Bustamante y Rivero, Cerro Colorado,
Arequipa, Peru. E-mail: emontesma@unsa.edu.pe